Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Potential Lawsuits Causing Zantac Manufacturers Heartburn
04:10pm, Monday, 15'th Aug 2022
Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
04:33pm, Friday, 12'th Aug 2022
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
Pharma companies see sales slump amid ongoing Zantac litigation
04:22pm, Friday, 12'th Aug 2022
Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.
Drugmaker stocks slammed over Zantac lawsuit concerns
02:20pm, Friday, 12'th Aug 2022
Thousands of lawsuits have been filed against companies including Sanofi, GlaxoSmithKline, Haleon and Pfizer accusing them of failing to properly warn users of the recalled heartburn drugs' health ris
GSK and Sanofi Push Back on Zantac Worries. Shares Rebounded.
10:49am, Friday, 12'th Aug 2022
After a UBS analyst's note sparked a two-day plunge in the drug makers, their shares rallied Friday after they said there is no evidence the heartburn drug causes cancer. A J.P. Morgan note also calle
Drugmakers' shares tumble on growing investor fears over Zantac litigation
09:12am, Friday, 12'th Aug 2022
CNBC's Julianna Tatelbaum discusses U.S. litigation focused on heartburn drug Zantac.
GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump
04:24am, Friday, 12'th Aug 2022
Shares in GSK, Sanofi
Sanofi upped to hold at Deutsche Bank as Zantac fears make a sell 'egregious'
03:41am, Friday, 12'th Aug 2022
Sanofi SNY, -3.94% SAN, +0.25% was upgraded to hold from sell at Deutsche Bank, after the heavy selling over the previous two days on worries about Zantac heartburn medication litigation. The first tr
European shares eke out gains at open as healthcare stocks rebound
03:28am, Friday, 12'th Aug 2022
European shares eked out gains on Friday at the open after Sanofi and GSK led a rebound in healthcare stocks, with the main STOXX 600 index set for weekly gains.
GSK, PFE, SNY Stocks Fall on Zantac Litigation
11:34am, Thursday, 11'th Aug 2022
Source: Willy Barton / Shutterstock.com Investors in GSK (NYSE: GSK ) stock, Pfizer (NYSE: PFE ) and Sanofi (NASDAQ: SNY ) are all feeling the heat today. Reportedly, they're concerned about legal pos
Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms
10:38am, Thursday, 11'th Aug 2022
Pharmaceutical stocks GSK, Sanofi and Haleon extended deep losses Thursday amid looming litigation around recalled heartburn drug Zantac. The post Pharma Stocks GSK, Sanofi And Haleon Lose Billions As
Drug stocks under pressure over Zantac litigation concerns
10:35am, Thursday, 11'th Aug 2022
Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins CNBC's 'Squawk Box' to discuss alleged concerns that Sanofi and GSK's antacid drug Zantac causes cancer.
GSK, Sanofi and Haleon slump on worries over Zantac litigation
07:18am, Thursday, 11'th Aug 2022
European-listed shares of drugmakers Haleon HLN, -11.81% , GSK GSK, -8.48% and Sanofi SAN, -8.81% plunged on Thursday on worries over the Zantac heartburn medication litigation. The first trial is set
China's Innovent Biologics secures over $300 million investment from Sanofi
08:37pm, Thursday, 04'th Aug 2022
Innovent Biologics Inc said on Friday Paris-based Sanofi SA would invest HK$2.42 billion ($307.88 million) in the biopharmaceutical group to jointly develop two cancer drugs in China.
How Siga Is Turning Its Biowarfare Soldier Onto This Outbreak
08:00am, Thursday, 04'th Aug 2022
The medicine Siga Technologies developed to combat biowarfare is now being used in the ongoing viral outbreak, and Siga stock has exploded.
